Choice of observational study design impacts on measurement of antipsychotic risks in the elderly: a systematic review

BMC Medical Research Methodology

Philip Ryan²  Amy Salter²  Elizabeth E Roughead¹  Nicole Pratt¹ 

[1] Quality Use of Medicines and Pharmacy Research Centre; Sansom Institute, University of South Australia, Adelaide, Australia;Discipline of Public Health, School of Population Health and Clinical Practice, University of Adelaide, Adelaide, Australia

关键词: Hospitalisation;    Pneumonia;    Hip fracture;    Stroke;    Cerebrovascular events;    Death;    Review;    Antipsychotics;   

Others  :  1136643
DOI  :  10.1186/1471-2288-12-72

 received in 2011-06-22, accepted in 2012-04-18,  发布年份 2012

【 摘 要 】

Background

Antipsychotics are frequently and increasingly prescribed to treat the behavioural symptoms associated with dementia despite their modest efficacy. Evidence regarding the potential adverse events of antipsychotics is limited and little is known about the longer-term safety of these medicines in the elderly. The aim of this review was to determine the impact of the choice of observational study design and methods used to control for confounding on the measurement of antipsychotic risks in elderly patients.

Methods

We searched PUBMED and the Cochrane controlled trials register for double-blind randomised controlled trials (RCTs), meta-analyses and published observational studies of antipsychotics.

Results

Forty four studies were identified for the endpoints; death, cerebrovascular events, hip fracture and pneumonia. RCTs found a 20% to 30% increased risk of death, or an absolute increase of 1extra death per 100 patients with atypical antipsychotics compared to non-use. Cohort and instrumental variable analyses estimated between 2 to 7 extra deaths per 100 patients with conventional compared to atypical antipsychotics. RCTs found a 2 to 3 times increased risk of all cerebrovascular events with atypical antipsychotics compared to placebo and no association with serious stroke that required hospitalisation. Observational studies using cohort and self-controlled case-series designs reported similar results; no association where the endpoint was stroke causing hospitalisation and a doubling of risk when minor stroke was included. No RCTs were available for the outcome of hip fracture or pneumonia. Observational studies reported a 20% to 40% increased risk of hip fracture with both antipsychotic classes compared to non-use. The risk of pneumonia was a 2 to 3 times greater with both classes compared to non-use while a self-controlled case-series study estimated a 60% increased risk. Conventional antipsychotics were associated with a 50% greater hip fracture risk than atypical antipsychotics, while the risk of pneumonia was similar between the classes.

Conclusions

Choice of observational study design is critical in studying the adverse effects of antispychotics. Cohort and instrumental variable analyses gave more consistent results to clinical studies for mortality outcomes as have self-controlled case-series for the risk of cerebrovascular events and stroke. Observational evidence has highlighted the potential for antipsychotics to be associated with serious adverse events that were not reported in RCTs including hip fracture and pneumonia. Good quality observational studies are required, that employ appropriate study designs that are robust towards unmeasured confounding, to confirm the potential excess risk of hip fracture and pneumonia with antipsychotics.

【 授权许可】

   
2012 Pratt et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1 .

【 参考文献 】

• [1]Ballard C, Waite J: The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev 2006, 1:CD003476.
• [2]Lonergan E, Luxenberg J, Colford J: Haloperidol for agitation in dementia. Cochrane Database Syst Rev 2002, 2:CD002852.
• [3]Ballard C, Fossey J, Sharp S: Antipsychotics in patients with Alzheimer’s disease–what is their clinical value? Nat Clin Pract Neurol 2007, 3(5):248-249.
• [4]De Deyn PP, Katz IR, Brodaty H, Lyons B, Greenspan A, Burns A: Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone. Clin Neurol Neurosurg 2005, 107(6):497-508.
• [5]Katz I, de Deyn PP, Mintzer J, Greenspan A, Zhu Y, Brodaty H: The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer’s disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. Int J Geriatr Psychiatry 2007, 22(5):475-484.
• [6]Schneider LS, Dagerman K, Insel PS: Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006, 14(3):191-210.
• [7]Schneider LS, Tariot PN, Dagerman KS, et al.: Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med 2006, 355(15):1525-1538.
• [8]De Deyn PP, Rabheru K, Rasmussen A, et al.: A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999, 53(5):946-955.
• [9]van Iersel MB, Zuidema SU, Koopmans RT, Verhey FR: Olde Rikkert MG. Antipsychotics for behavioural and psychological problems in elderly people with dementia: a systematic review of adverse events. Drugs Aging 2005, 22(10):845-858.
• [10]Sacchetti E, Turrina C, Valsecchi P: Cerebrovascular accidents in elderly people treated with antipsychotic drugs: a systematic review. Drug Saf 2010, 33(4):273-288.
• [11]Takkouche B, Montes-Martinez A, Gill SS, Etminan M: Psychotropic medications and the risk of fracture: a meta-analysis. Drug Saf 2007, 30(2):171-184.
• [12]Trifiro G: Antipsychotic drug use and community-acquired pneumonia. Curr Infect Dis Rep 2011, 13(3):262-268.
• [13]Trifiro G, Spina E, Gambassi G: Use of antipsychotics in elderly patients with dementia: do atypical and conventional agents have a similar safety profile? Pharmacol Res 2009, 59(1):1-12.
• [14]Brookhart MA, Wang PS, Solomon DH, Schneeweiss S: Instrumental variable analysis of secondary pharmacoepidemiologic data. Epidemiology 2006, 17(4):373-374.
• [15]Greenland S: An introduction To instrumental variables for epidemiologists. Int J Epidemiol 2000, 29(6):1102.
• [16]Martens EP, Pestman WR, de Boer A, Belitser SV, Klungel OH: Instrumental variables: application and limitations. Epidemiology 2006, 17(3):260-267.
• [17]Whitaker HJ, Farrington CP, Spiessens B, Musonda P: Tutorial in biostatistics: the self-controlled case series method. Stat Med 2006, 25(10):1768-1797.
• [18]Merlin T, Weston A, Tooher R: Extending an evidence hierarchy to include topics other than treatment: revising the Australian ‘levels of evidence’. BMC Med Res Methodol 2009, 9:34. BioMed Central Full Text
• [19]Schneider LS, Dagerman KS, Insel P: Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005, 294(15):1934-1943.
• [20]Haupt M, Cruz-Jentoft A, Jeste D: Mortality in elderly dementia patients treated with risperidone. J Clin Psychopharmacol 2006, 26(6):566-570.
• [21]Ballard C, Hanney ML, Theodoulou M, et al.: The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 2009, 8(2):151-157.
• [22]Gill SS, Bronskill SE, Normand SL, et al.: Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007, 146(11):775-786.
• [23]Trifiro G, Verhamme KM, Ziere G, Caputi AP, Ch Stricker BH, Sturkenboom MC: All-cause mortality associated with atypical and typical antipsychotics in demented outpatients. Pharmacoepidemiol Drug Saf 2007, 16(5):538-544.
• [24]Raivio MM, Laurila JV, Strandberg TE, Tilvis RS, Pitkala KH: Neither atypical nor conventional antipsychotics increase mortality or hospital admissions among elderly patients with dementia: a two-year prospective study. Am J Geriatr Psychiatry 2007, 15(5):416-424.
• [25]Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT: Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001, 58(12):1161-1167.
• [26]Kales HC, Valenstein M, Kim HM, et al.: Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry 2007, 164(10):1568-1576. quiz 1623
• [27]Hollis J, Grayson D, Forrester L, Brodaty H, Touyz S, Cumming R: Antipsychotic medication dispensing and risk of death in veterans and war widows 65 years and older. Am J Geriatr Psychiatry 2007, 15(11):932-941.
• [28]Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS: Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. Cmaj 2007, 176(5):627-632.
• [29]Wang PS, Schneeweiss S, Avorn J, et al.: Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005, 353(22):2335-2341.
• [30]Liperoti R, Onder G, Landi F, et al.: All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study. J Clin Psychiatry 2009, 70(10):1340-1347.
• [31]Pratt NL, Roughead EE, Salter A, Ryan P: Antipsychotics and the risk of death in the elderly: an instrumental variable analysis using two preference based instruments. Pharmacoepidemiol Drug Saf 2010, 19(7):699-707.
• [32]Herrmann N, Lanctot KL: Do atypical antipsychotics cause stroke? CNS Drugs 2005, 19(2):91-103.
• [33]Sacchetti E, Trifiro G, Caputi A, et al.: Risk of stroke with typical and atypical anti-psychotics: a retrospective cohort study including unexposed subjects. J Psychopharmacol 2008, 22(1):39-46.
• [34]Barnett MJ, Wehring H, Perry PJ: Comparison of risk of cerebrovascular events in an elderly VA population with dementia between antipsychotic and nonantipsychotic users. J Clin Psychopharmacol 2007, 27(6):595-601.
• [35]Kolanowski A, Fick D, Waller JL, Ahern F: Outcomes of antipsychotic drug use in community-dwelling elders with dementia. Arch Psychiatr Nurs 2006, 20(5):217-225.
• [36]Liperoti R, Gambassi G, Lapane KL, et al.: Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Clin Psychiatry 2005, 66(9):1090-1096.
• [37]Douglas IJ, Smeeth L: Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ 2008, 337:a1227.
• [38]Pratt NL, Roughead EE, Ramsay E, Salter A, Ryan P: Risk of hospitalisation for stroke associated with antipsychotic use in the elderly: a self controlled case-series result. Drugs Aging 2010, 27(11):885-893.
• [39]Percudani M, Barbui C, Fortino I, Tansella M, Petrovich L: Second-generation antipsychotics and risk of cerebrovascular accidents in the elderly. J Clin Psychopharmacol 2005, 25(5):468-70.
• [40]Sacchetti E, Turrina C, Cesana B, Mazzaglia G: Timing of stroke in elderly people exposed to typical and atypical antipsychotics: a replication cohort study after the paper of Kleijer, et al. J Psychopharmacol 2010, 24(7):1131-2.
• [41]Kleijer BC, van Marum RJ, Egberts AC, Jansen PA, Knol W, Heerdink ER: Risk of cerebrovascular events in elderly users of antipsychotics. J Psychopharmacol 2008.
• [42]Herrmann N, Mamdani M, Lanctot KL: Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry 2004, 161(6):1113-5.
• [43]Gill SS, Rochon PA, Herrmann N, et al.: Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 2005, 330(7489):445.
• [44]Finkel S, Kozma C, Long S, Greenspan A, Mahmoud R, Baser O, Engelhart L: Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics. Int Psychogeriatr 2005, 17(4):617-29.
• [45]Wang PS, Schneeweiss S, Setoguchi S, et al.: Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications. J Clin Psychopharmacol 2007, 27(6):707-10.
• [46]Normand SL, Sykora K, Li P, Mamdani M, Rochon PA, Anderson GM: Readers guide to critical appraisal of cohort studies: 3. Analytical strategies to reduce confounding. BMJ 2005, 330(7498):1021-3.
• [47]Liperoti R, Onder G, Lapane KL, et al.: Conventional or atypical antipsychotics and the risk of femur fracture among elderly patients: results of a case–control study. J Clin Psychiatry 2007, 68(6):929-34.
• [48]Pouwels S, van Staa TP, Egberts AC, Leufkens HG, Cooper C, de Vries F: Antipsychotic use and the risk of hip/femur fracture: a population-based case–control study. Osteoporos Int 2009, 20(9):1499-506.
• [49]Jalbert JJ, Eaton CB, Miller SC, Lapane KL: Antipsychotic use and the risk of hip fracture among older adults afflicted with dementia. J Am Med Dir Assoc 2010, 11(2):120-7.
• [50]Pratt N, Roughead EE, Ramsay E, Salter A, Ryan P: Risk of hospitalization for hip fracture and pneumonia associated with antipsychotic prescribing in the elderly: a self-controlled case-series analysis in an Australian health care claims database. Drug Saf 2011, 34(7):567-75.
• [51]Wang PS, Bohn RL, Glynn RJ, Mogun H, Avorn J: Hazardous benzodiazepine regimens in the elderly: effects of half-life, dosage, and duration on risk of hip fracture. Am J Psychiatry 2001, 158(6):892-8.
• [52]Knol W, van Marum RJ, Jansen PA, Souverein PC, Schobben AF, Egberts AC: Antipsychotic drug use and risk of pneumonia in elderly people. J Am Geriatr Soc 2008, 56(4):661-6.
• [53]Trifiro G, Gambassi G, Sen EF, et al.: Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested case–control study. Ann Intern Med 2010, 152(7):418-25. W139-40
• [54]Gau JT, Acharya U, Khan S, Heh V, Mody L, Kao TC: Pharmacotherapy and the risk for community-acquired pneumonia. BMC Geriatr 2010, 10:45. BioMed Central Full Text
• [55]Wada H, Nakajoh K, Satoh-Nakagawa T, et al.: Risk factors of aspiration pneumonia in Alzheimer’s disease patients. Gerontology 2001, 47(5):271-6.
• [56]Hollis J, Forrester L, Brodaty H, Touyz S, Cumming R, Grayson D: Risk of death associated with antipsychotic drug dispensing in residential aged care facilities. Aust N Z J Psychiatry 2007, 41(9):751-758.
• [57]Rothman KJ, Greenland S, Lash TL: Modern epidemiology. 3rd edition. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia; 2008.
• [58]Kuehn BM: FDA warns antipsychotic drugs may be risky for elderly. JAMA 2005, 293(20):2462.
• [59]Star K, Bate A, Meyboom RH, Edwards IR: Pneumonia following antipsychotic prescriptions in electronic health records: a patient safety concern? Br J Gen Pract 2010, 60(579):e385-94.
• [60]Concato J, Shah N, Horwitz RI: Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000, 342(25):1887-92.
• [61]Brodaty H, Ames D, Snowdon J, et al.: Risperidone for psychosis of Alzheimer’s disease and mixed dementia: results of a double-blind, placebo-controlled trial. Int J Geriatr Psychiatry 2005, 20(12):1153-7.
• [62]Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M: Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999, 60(2):107-15.
• [63]Sultzer DL, Davis SM, Tariot PN, et al.: Clinical symptom responses to atypical antipsychotic medications in Alzheimer’s disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry 2008, 165(7):844-54.